News

Stop TB Partnership Craig David Video Series #2

This is the second video in the series: “This is All Worthwhile”

Craig David with South African Schoolchildren

In this clip Craig talks to children about the effects of tuberculosis on young people, particularly the stigma they may face among their peers. He urges them to recognize the symptoms of tuberculosis and ask for help from a parent or teacher if they think they might be infected, reminding them that tuberculosis can be cured.

We see Craig interacting with kids outside the school, kicking around a football in the street, and sitting in the classroom, where he gives a poignant a cappella rendition of his hit “Walking Away”, accompanied by the delighted children beating out a rhythm on their desktops as he sings “I’m walking away… to find a better day”.

Visibly moved, Craig tells the group: “You guys, the fact that you understand it and you are aware makes me feel like this is all worthwhile.”

The video was produced by Fabrica – Benetton’s Research Centre on Communications. Four more videos will be released, one each week, between now and 7 July.

More News
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...